Literature DB >> 16110498

Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a pediatric oncology group phase I study.

Mark L Greenberg1, Paul G Fisher, Carolyn Freeman, David N Korones, Mark Bernstein, Henry Friedman, Susan Blaney, Linda Hershon, Tianni Zhou, Zhengjia Chen, Cynthia Kretschmar.   

Abstract

BACKGROUND: Brainstem gliomas (BSGs) are resistant to all therapy. Based on their imaging characteristics, we postulated that inhibition of P-glycoprotein (P-gp) associated with endothelial cells of the blood-brain barrier might enhance penetration of xenobiotic antineoplastics. PROCEDURE: Seven patients were enrolled in a Phase I study of etoposide, continuous infusion cyclosporine A given with and escalating doses of vincristine and concomitant standard-dose irradiation.
RESULTS: Six patients were entered at the first level and one at the second. Closure of the study was mandated by dose-limiting neurotoxicity, consisting of seizures associated with white-matter changes, and alteration of consciousness with bulbar signs. One patient had tumor necrosis at 6 weeks, suggesting some tumor effect. Median survival for the group was 11 months, and for the patients who completed more than 1 month of therapy it was 11 months.
CONCLUSION: This regimen proved excessively toxic.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16110498     DOI: 10.1002/pbc.20382

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  9 in total

1.  Protein profiling of formalin fixed paraffin embedded tissue: Identification of potential biomarkers for pediatric brainstem glioma.

Authors:  Javad Nazarian; Mariarita Santi; Yetrib Hathout; Tobey J Macdonald
Journal:  Proteomics Clin Appl       Date:  2008-06       Impact factor: 3.494

Review 2.  Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope?

Authors:  Kenneth J Cohen; Nada Jabado; Jacques Grill
Journal:  Neuro Oncol       Date:  2017-08-01       Impact factor: 12.300

3.  Clinico-radiologic characteristics of long-term survivors of diffuse intrinsic pontine glioma.

Authors:  Sadhana Jackson; Zoltan Patay; Robyn Howarth; Atmaram S Pai Panandiker; Arzu Onar-Thomas; Amar Gajjar; Alberto Broniscer
Journal:  J Neurooncol       Date:  2013-06-29       Impact factor: 4.130

4.  Diffuse intrinsic pontine glioma: poised for progress.

Authors:  Katherine E Warren
Journal:  Front Oncol       Date:  2012-12-28       Impact factor: 6.244

5.  Survival with concurrent temozolomide and radiotherapy in pediatric brainstem glioma with relation to the tumor volume.

Authors:  Shachi Jain Taran; Rakesh Taran; Manika Batra; Deah Deepak Ladia; Virendra Bhandari
Journal:  J Pediatr Neurosci       Date:  2015 Oct-Dec

Review 6.  Role of Radiation Therapy in the Management of Diffuse Intrinsic Pontine Glioma: A Systematic Review.

Authors:  Matthew Gallitto; Stanislav Lazarev; Isaac Wasserman; James M Stafford; Suzanne L Wolden; Stephanie A Terezakis; Ranjit S Bindra; Richard L Bakst
Journal:  Adv Radiat Oncol       Date:  2019-03-30

7.  Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report.

Authors:  Jack M Su; Lindsay B Kilburn; David B Mansur; Mark Krailo; Allen Buxton; Adesina Adekunle; Amar Gajjar; Peter C Adamson; Brenda Weigel; Elizabeth Fox; Susan M Blaney; Maryam Fouladi
Journal:  Neuro Oncol       Date:  2022-04-01       Impact factor: 13.029

Review 8.  DIPG in Children - What Can We Learn from the Past?

Authors:  Magimairajan Issai Vanan; David D Eisenstat
Journal:  Front Oncol       Date:  2015-10-21       Impact factor: 6.244

Review 9.  Beyond the Blood:Brain Barrier: The Importance of Central Nervous System (CNS) Pharmacokinetics for the Treatment of CNS Tumors, Including Diffuse Intrinsic Pontine Glioma.

Authors:  Katherine Elizabeth Warren
Journal:  Front Oncol       Date:  2018-07-03       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.